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Plasma total cysteine, pregnancy complications, and adverse
pregnancy outcomes: the Hordaland Homocysteine Study1–3
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ABSTRACT
Background: Total homocysteine (tHcy) is associated with preg-
nancy complications and adverse pregnancy outcomes. The asso-
ciations of plasma total cysteine (tCys) with such outcomes have
not been investigated in large populations.
Objective: We investigated the association between plasma tCys
and pregnancy complications, congenital malformations, and other
adverse pregnancy outcomes.
Design: The plasma tCys concentrations of 5883 women aged
40–42 y that were measured in 1992–1993 during a cardiovas-
cular health screening were compared with the outcomes and
complications of 14 492 pregnancies in the same women that
were registered in the Medical Birth Registry of Norway from
1967 to 1996.
Results: After adjustment for parity, mother’s age, tHcy, total cho-
lesterol, body mass index, smoking, and coffee drinking, high
plasma tCys concentrations (above the 95th percentile) were asso-
ciated with significantly higher risks of preeclampsia [n = 342;
odds ratio (OR): 1.6; 95% CI: 1.1, 2.4; P = 0.03], premature deliv-
ery (n = 774; OR: 1.8; 95% CI: 1.3, 2.5; P = 0.001), and very low
birth weight (n = 175; OR: 2.0; 95% CI: 1.1, 3.9; P = 0.03) than
were lower plasma tCys concentrations. tCys was not associated
with the risk of placental abruption. High tCys concentrations
showed a weak association with congenital malformations and
stillbirths with birth weight < 1500 g. The associations were inde-
pendent of the tHcy concentrations.
Conclusion: High tCys concentrations were associated with risks
of preeclampsia, premature delivery, and low birth weight. Am
J Clin Nutr 2003;77:467–72.
KEY WORDS Plasma total cysteine, pregnancy complications,
preeclampsia, pregnancy outcomes, total homocysteine, Hordaland
Homocysteine Study, Norway, women
INTRODUCTION
High concentrations of plasma total homocysteine (tHcy) are
associated with serious pregnancy complications, including
pregnancy-induced hypertension, preeclampsia (1), and placental
abruption (2), and with adverse pregnancy outcomes such as neu-
ral tube defects (3). Furthermore, an elevated plasma tHcy con-
centration is regarded as a risk factor for atherosclerosis (4, 5) and
venous thrombosis (6).
The mechanism by which hyperhomocysteinemia confers
increased risks of pregnancy complications and adverse outcomes
is not yet known. Low dietary folate intakes and low circulating
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folate concentrations during pregnancy are associated with
increased risks of preterm delivery, infant low birth weight, fetal
growth retardation, and neural tube defects (7). One metabolic
effect of folate deficiency is an elevated plasma tHcy concen-
tration. It is not yet known whether an elevated tHcy concentra-
tion is harmful by itself through its vascular effect or is merely
a reflection of the folate status. It was proposed that elevated
tHcy causes endothelial dysfunction; therefore, women with
hyperhomocysteinemia may be prone to endothelial dysfunction
in the placental vasculature (8, 9). An elevated tHcy concentra-
tion and impaired folate status may also affect biological methy-
lation and DNA synthesis (10) and thereby cell proliferation and
normal fetal growth.
Cysteine is another sulfhydryl amino acid with structural
and chemical properties similar to those of homocysteine (11).
The concentration of total cysteine (tCys) in the serum or
plasma of healthy subjects is 250 mol/L, which is 20-fold
that of plasma tHcy (12). Several studies found that tCys is
associated with the risk of vascular disease in the coronary,
cerebral, and peripheral arteries (13–17). However, the rela-
tion between tCys and pregnancy complications or adverse
outcomes has received little attention. Raijmakers et al (18)
reported that preeclamptic women had higher plasma cysteine
and homocysteine concentrations during pregnancy than did
women without preeclampsia.
The Hordaland Homocysteine Study included measurements
of plasma tCys and tHcy concentrations in men and women
aged 40–42 y and 65–67 y in 1992–1993. In this study, the
major determinants of tCys concentration were body mass
index (BMI; in kg/m2), diastolic blood pressure, total choles-
terol, and coffee drinking (19). Almost 93% of the 40–42-y-old
women who participated in the Hordaland study were regis-
tered with ≥ 1 pregnancy in the Medical Birth Registry of Nor-
way. tHcy was found to be associated with common pregnancy
complications and adverse pregnancy outcomes in this popu-
lation (20). In the present study, we investigated the relation
between tCys concentrations measured in 1992–1993 and
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TABLE 1
Characteristics of the 5883 women in 1992–1993 by low or high total cysteine (tCys) concentration1
tCys concentration
Percentage < 304 mol/L ≥ 304 mol/L
Characteristic of total n (n = 5594) (n = 289) P
n (%) n (%)
> 5 cups coffee/d 2275 (38.7) 2138 (38.2) 137 (47.4) 0.0018
Ever a smoker 3624 (61.7) 3450 (61.7) 174 (60.2) 0.6015
No use of vitamins2 971 (22.5) 922 (22.4) 49 (24.9) 0.4191
BMI (in kg/m2) > 30 387 (6.6) 329 (5.9) 58 (20.1) < 0.0001
DBP > 90 mm Hg 542 (9.2) 492 (8.8) 50 (17.3) < 0.0001
tHcy > 12 mol/L 817 (13.9) 726 (13.0) 91 (31.5) < 0.0001
Cholesterol > 6.5 mmol/L 685 (11.6) 634 (11.3) 51 (17.7) 0.0011
1 n in brackets. DBP, diastolic blood pressure; tHcy, total homocysteine.
2 Data on vitamin intakes were obtained from only 4311 women.
pregnancy complications and outcomes registered from 1967
to 1996.
SUBJECTS AND METHODS
Study population
In 1992–1993, baseline data for the Hordaland Homocys-
teine Study were collected by the National Health Screening
Services in cooperation with the University of Bergen, Norway.
A total of 18 043 men and woman aged 40–67 y participated
in the cardiovascular health screening. The screening included
measurements of height, weight, blood pressure, heart rate,
serum total cholesterol, serum triacylglycerol, tHcy, and tCys.
Information about lifestyle, diet, and reproductive history was
collected with the use of self-administered questionnaires.
Details on the data collection were published previously (21).
Plasma tCys and tHcy concentrations were measured by using
a fully automated assay featuring precolumn derivatization with
monobromobimane followed by HPLC separation and fluores-
cence detection (22, 23).
Since 1967, the Medical Birth Registry has received notifica-
tion of all births with a gestation > 16 wk. The notification
included information about birth weight, length of gestation,
medical conditions, complications during pregnancy and birth,
congenital malformations, and obstetrical interventions. All
women aged 40–42 y who participated in the Hordaland Homo-
cysteine Study were linked with data from 1967 to 1996 filed by
the Medical Birth Registry of Norway. Among the 5883 women,
14 492 pregnancies were reported to the registry during
1967–1996.
Statistical methods
The relations between tCys and pregnancy complications and
adverse pregnancy outcomes were studied with logistic regression.
With the use of PROC GENMOD of SAS (release 8.2 for HP-Unix;
SAS Institute Inc, Cary, NC), the dependence of a given pregnancy
outcome on other pregnancy outcomes in the same woman was taken
into account by performing logistic regression analyses for clustered
binary data with the use of generalized estimating equations (GEE)
methodology. The analyses were performed both by using tCys quar-
tiles and by using tCys as a binary variable with the 95th percentile
as the cutoff value. Because no associations with outcomes were
observed over quartiles, we report the results only with the latter rep-
resentation of tCys. Hence, we report odds ratios (ORs) and 95%
CIs of the comparison between tCys concentrations above and below
the 95th percentile. The ORs are presented with adjustment for the
mother’s age at delivery, parity, tHcy, BMI, total cholesterol, smok-
ing habits, and coffee drinking. All analyses were repeated separately
for the years from 1980 to 1996, which were closer in time to the
tCys measurements and hence more likely to show stronger associ-
ations between tCys and pregnancy complications and outcomes.
However, there was no general tendency to strengthen the results;
therefore, we mostly present results from 1967–1996.
The analyses were also performed for different combinations
of low (< 250 mol/L), medium (250–300 mol/L), and high
(≥ 300 mol/L) tCys concentrations and low (< 12 mol/L) and
high (≥ 12 mol/L) tHcy concentrations. Subjects with a low tCys
concentration and a low tHcy concentration served as the refer-
ence category. Statistical analyses were performed with SAS sta-
tistical software (release 8.2 for HP-Unix; SAS Institute Inc).
RESULTS
Study population
The characteristics of the 5883 women who were 40–42 y old at the
time of the tCys measurements in 1992–1993 are shown in Table 1.
The mean (± SD) tCys concentration was 252.6 ± 29.5 mol/L. The
women with a tCys concentration above the 95th percentile drank
significantly more coffee and had significantly higher BMI values,
diastolic blood pressure, and cholesterol and tHcy concentrations
than did those with a lower tCys concentration.
Total cysteine, pregnancy complications, and adverse
pregnancy outcomes
The ORs for pregnancy complications and adverse pregnancy
outcomes of the women with a baseline tCys concentration above
the 95th percentile compared with those with a lower tCys con-
centration are shown in Table 2. The results were adjusted for par-
ity and mother’s age at delivery. Additional adjustments were per-
formed for tHcy, BMI, cholesterol, smoking, and coffee intake.
Additional adjustment for blood pressure slightly weakened the
association between tCys and preeclampsia but had no effect on
the other associations (data not shown).
High tCys concentrations were strongly associated with
preeclampsia (Table 2). Preeclampsia was negatively associated
with smoking and strongly and positively associated with BMI
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TABLE 2
Odds ratios (ORs) for pregnancy complications and adverse pregnancy outcomes of women with a high (above the 95th percentile) total cysteine (tCys)
concentration (≥304 mmol/L) compared with those with a lower tCys concentration (<304 mol/L)
Adjusted for parity and mother’s age Adjusted for multiple factors2
Complication or outcome OR1 P OR1 P
Preeclampsia 0.0001 0.03
<304 mol/L (n = 308) 1 1
≥304 mol/L (n = 34) 2.3 (1.6, 3.5) 1.6 (1.1, 2.4)
Preeclampsia < 37 wk 0.09 0.11
<304 mol/L (n = 46) 1 1
≥304 mol/L (n = 5) 2.6 (0.9, 7.8) 2.4 (0.8, 7.2)
Placental abruption 0.8 0.7
<304 mol/L (n = 70) 1 1
≥304 mol/L (n = 4) 0.8 (0.3, 2.7) 0.8 (0.3, 2.4)
Premature delivery (<37 wk) 0.0008 0.001
<304 mol/L (n = 712) 1 1
≥304 mol/L (n = 62) 1.7 (1.3, 2.4) 1.8 (1.3, 2.5)
Premature delivery (<32 wk) 0.1 0.1
<304 mol/L (n = 176) 1 1
≥304 mol/L (n = 15) 1.6 (0.8, 3.1) 1.6 (0.8, 3.2)
Low birth weight (<2500 g) 0.08 0.07
<304 mol/L (n = 664) 1 1
≥304 mol/L (n = 47) 1.4 (1.0, 2.0) 1.4 (1.0, 2.1)
Very low birth weight (<1500 g) 0.04 0.03
<304 mol/L (n = 159) 1 1
≥304 mol/L (n = 16) 1.9 (1.0, 3.6) 2.0 (1.1, 3.9)
Stillbirth 0.3 0.3
<304 mol/L (n = 167) 1 1
≥304 mol/L (n = 13) 1.4 (0.7, 2.8) 1.5 (0.7, 3.0)
Stillbirth < 1500 g 0.09 0.07
<304 mol/L (n = 104) 1 1
≥304 mol/L (n = 11) 2.0 (0.9, 4.2) 2.1 (0.9, 4.5)
Neonatal mortality (first week) 0.2 0.4
<304 mol/L (n = 53) 1 1
≥304 mol/L (n = 5) 1.8 (0.7, 4.5) 1.5 (0.6, 4.1)
1 95% CI in parentheses.
2 Parity, mother’s age, total homocysteine, cholesterol, body mass index, smoking, and coffee drinking.
(data not shown). Adjustment for smoking and BMI slightly weak-
ened the relation between tCys and preeclampsia (data not shown).
There was no association when only births from 1980 to 1996
were considered (OR: 1.2; 95% CI: 0.6, 2.3; P = 0.7). The relation
between tCys and preeclampsia was not significant when preg-
nancy was shorter than 37 wk although the point estimate was
stronger (Table 2).
Placental abruption was reported in 0.5% of the pregnancies. High
tCys concentrations were not associated with placental abruption.
There was a strong association between tCys concentrations
and premature delivery defined as a gestation of < 37 wk. The
association was stronger for the time period closest to the tCys
measurement (ie, 1980–1996) (OR: 2.0; 95% CI: 1.1, 3.5; P = 0.01)
than for the period of 1967–1996. However, the association
between tCys concentrations and premature delivery was not
significant when gestation was < 32 wk (Table 2).
There was a weak association between tCys concentrations and low
birth weight, which was defined as < 2500 g. However, there was a
much stronger and significant association between tCys concentrations
and very low birth weight, which was defined as < 1500 g (Table 2).
There was a weak and nonsignificant association between
tCys concentrations and stillbirths (n = 180). However, when
birth weight was considered, tCys was strongly associated with
stillbirths in which birth weight was < 1500 g. tCys was also
weakly associated with neonatal mortality during the first week
of life (Table 2).
Total cysteine and congenital malformations
Among the 14 492 pregnancies, ≥ 1 malformation was reported
for 191 pregnancies. After adjustment for parity, mother’s age, tHcy,
cholesterol, BMI, smoking, and coffee drinking, there was a weak
association between tCys and the risk of all malformations combined
(OR: 1.7; 95% CI: 1.0, 2.8; P = 0.06). None of the relations between
tCys and specific malformations were significant (data not shown).
Combinations of total cysteine and total homocysteine and
the risk of pregnancy complications and adverse pregnancy
outcomes
We investigated a combination variable of tCys and tHcy in
relation to the risk of the outcomes studied (Table 3). The com-
bination of low tCys and low tHcy was used as the reference cat-
egory. Increased risks of preeclampsia, premature delivery, and
low birth weight were seen in subjects having the combinations
of high tCys and low tHcy or high tCys and high tHcy. Similar
trends were observed for all the other pregnancy complications
and adverse pregnancy outcomes that were investigated in this
study. However, for placental abruption, an increased risk was
seen in subjects having the combination of low tCys and high
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TABLE 3
Odds ratios (ORs) for pregnancy complications and adverse pregnancy outcomes of various combinations of total cysteine (tCys) and total homocysteine
(tHcy) concentrations1
OR for OR for premature OR for low birth
preeclampsia2 delivery (<37 wk)2 weight (<2500 g)2
Low tCys, low tHcy (n = 2577) 1 [172] 1 [342] 1 [295]
Medium tCys, low tHcy (n = 2207) 1.1 (0.8, 1.4) [164] 0.8 (0.7, 1.0) [245] 1.0 (0.8, 1.2) [258]
High tCys, low tHcy (n = 243) 1.7 (1.0, 2.7) [33] 1.4 (0.9, 2.1) [44] 1.4 (0.9, 2.2) [39]
Low tCys, high tHcy (n = 257) 0.8 (0.4, 1.8) [16] 0.7 (0.4, 1.1) [28] 0.7 (0.4, 1.1) [28]
Medium tCys, high tHcy (n = 491) 1.2 (0.7, 2.1) [48] 1.1 (0.8, 1.5) [81] 0.9 (0.6, 1.3) [67]
High tCys, high tHcy (n = 108) 1.5 (0.7, 3.0) [18] 2.3 (1.4, 3.8) [34] 1.6 (0.9, 3.0) [24]
P for heterogeneity <0.3 <0.001 <0.02
P for interaction between tCys and tHcy 0.93 0.0015 0.23
1 Adjusted for parity, mother’s age, tHcy, cholesterol, body mass index, smoking, and coffee drinking. Concentration levels for tCys were defined as fol-
lows: low, <250 mol/L; medium, 250–300 mol/L; high, ≥300 mol/L. Concentration levels for tHcy were defined as follows: low, <12 mol/L; high,
≥12 mol/L.
2 95% CI in parentheses; n in brackets.
tHcy (data not shown). The interaction between tCys and tHcy
was also investigated by adding an interaction term to the model.
The results showed a significant interaction between tCys and
tHcy for premature delivery but not for preeclampsia or low birth
weight (Table 3).
DISCUSSION
By linking data on 5883 women aged 40–42 y from the Horda-
land Homocysteine Study with data from the Medical Birth Reg-
istry of Norway, we studied the relation between plasma tCys and
pregnancy complications and adverse pregnancy outcomes. The
results showed that high tCys concentrations are weakly associ-
ated with several complications and adverse outcomes, including
preeclampsia, premature delivery, low birth weight, and stillbirth.
Furthermore, tCys was weakly associated with congenital mal-
formations. These associations persisted after adjustment for tHcy
and other possible confounders.
In this study, concentrations of tCys above the 95th percentile
were associated with preeclampsia. Raijmakers et al (18) reported
higher tCys and tHcy concentrations during pregnancy in
preeclamptic women than in women without preeclampsia. In
agreement with this, an increased risk of preeclampsia was seen in
subjects having the combination of high tCys and high tHcy in the
present study (Table 3). Elevated concentrations of metabolites
during preeclampsia have been explained by the reduction of
plasma volume, which may be as much as 40% in severe cases
(24, 25). This cannot explain our findings, however, because the
tCys and tHcy concentrations were measured after rather than dur-
ing preeclampsia.
The role of tCys in the pathogenesis of pregnancy complica-
tions is not yet known. It has been proposed that elevated tHcy
concentrations cause endothelial dysfunction, and hyperhomo-
cysteinemia may provoke placental vascular dysfunction (8, 9).
Cysteine may affect the placental vasculature by a similar mech-
anism, but the possibility has not been investigated. Elevated tCys
concentrations may reflect renal impairment, which has consis-
tently been shown to cause increased concentrations of both tHcy
and tCys (26). This, however, does not explain why elevated tCys
concentrations are also a risk factor for pregnancy complications
and adverse pregnancy outcomes at low tHcy concentrations
(Table 3). In a previous study, which evaluated the relation
between tCys and the risk of cardiovascular disease, low tCys
concentrations were associated with the risk of cerebrovascular
and peripheral vascular disease (17). We proposed that low cys-
teine concentrations may be a marker of low glutathione concen-
trations (which were recently associated with an increased risk of
coronary artery disease) (27). However, in the present study, high
tCys concentrations rather than low ones were associated with
pregnancy complications and adverse pregnancy outcomes. There-
fore, the possibility of glutathione involvement is not plausible in
this case.
We considered the possibility that tCys may simply be a
marker for other risk factors associated with placental disease.
There is some evidence that adverse pregnancy outcomes are
associated with both coffee drinking (28) and BMI (29–31), and
we previously showed that both these factors are strong deter-
minants of tCys (19). However, the relations between tCys and
different complications and outcomes were upheld even after
adjustment for several possible confounders. This indicates that
tCys is not merely a marker for the risk factors evaluated in this
study.
Various pregnancy complications caused by impaired function
of the placental vascular bed are associated with both high tHcy
and high tCys concentrations (18). This is in accordance with an
increased risk of occlusive vascular disease conferred by high con-
centrations of these aminothiols (13–17). In the present study, we
observed no significant association between tCys and various con-
genital abnormalities, including neural tube defects, which have
been linked with hyperhomocysteinemia (32) and impaired folate
status (33). The lack of a significant relation between tCys and
congenital abnormalities may be explained by the fact that cys-
teine metabolism is independent of folate status (34). However,
insufficient power to detect such a relation because of the low
number of malformations in the subgroups with a high tCys con-
centration cannot be ruled out.
Most of the pregnancy complications and adverse pregnancy out-
comes evaluated in this study are in fact interrelated. Pregnancies
with very low birth weight (< 1500 g) overlap with premature deliv-
eries (gestation of < 37 wk) to a significant extent. In fact, all the
preeclamptic pregnancies having a duration of < 37 wk were a sub-
set of the premature deliveries (gestation of < 37 wk). Such a strong
interrelation between outcome measures prevents the disentangle-
ment of the primary lesions caused by elevated tCys concentrations.
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We exploited the possibility to retrospectively assess the rela-
tion between tCys and pregnancy complications by using data
from a study that previously showed strong associations between
tHcy and pregnancy complications and adverse pregnancy out-
comes (20). In this previous study, the risk of preeclampsia, pre-
mature delivery, very low birth weight, stillbirth, and different
congenital malformations increased over quartiles of tHcy con-
centration. tHcy was strongly associated with placental abrup-
tion only at very high tHcy concentrations (> 15 mol/L) (20).
In the present study, we found no associations with these preg-
nancy complications and adverse pregnancy outcomes over quar-
tiles. Furthermore, we found no association between tCys and
congenital malformations or between tCys and placental abrup-
tion even at tCys concentrations above the 95th percentile.
Finally, the relations to tCys were not strengthened when the
analyses were repeated for the time period closer to the tCys
measurements. Thus, the relation between tCys and pregnancy
complications and adverse pregnancy outcomes is much weaker
than that found for tHcy. Nevertheless, when a combination vari-
able of tCys and tHcy was investigated, the results (Table 3)
showed that an elevated tHcy concentration is not a risk factor
for preeclampsia, premature delivery, or low birth weight except
when the tCys concentration is elevated. Thus, the possibility of
interaction between tCys and tHcy in the pathogenesis of preg-
nancy complications and adverse pregnancy outcomes cannot be
ruled out.
In conclusion, our data show that high tCys concentrations are
associated with several pregnancy complications and adverse
pregnancy outcomes, including preeclampsia, premature deliv-
ery, and low birth weight. The associations were observed at both
high and low tHcy concentrations. This is the first large study to
evaluate the role of tCys in pregnancy complications and out-
comes. However, because tCys concentrations were measured
after the outcomes had occurred, we cannot rule out the possi-
bility that the pregnancy complications and adverse pregnancy
outcomes were caused by another factor that also caused elevated
tCys concentrations. Our results should be confirmed by prospec-
tive studies in which tCys concentrations are measured before
the pregnancy.
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